Literature DB >> 7858879

Role of endogenous endothelin in myocardial and coronary endothelial injury after ischaemia and reperfusion in rats: studies with bosentan, a mixed ETA-ETB antagonist.

V Richard1, N Kaeffer, M Hogie, C Tron, T Blanc, C Thuillez.   

Abstract

1. Previous studies suggested that endothelin-1 (ET-1) may play a role in myocardial ischaemia and reperfusion. This study was designed to test the effect of a new nonpeptide antagonist of endothelin ETA and ETB receptors, bosentan, on myocardial infarct size, ventricular arrhythmias, and coronary endothelial dysfunction after ischaemia and reperfusion. 2. Anaesthetized male Wistar rats were subjected to 20 min ischaemia (left coronary artery occlusion) followed by 1 h (for the evaluation of coronary endothelial dysfunction) or 2 h (for the evaluation of infarct size) reperfusion, or 5 min ischaemia followed by 15 min reperfusion (for the evaluation of reperfusion arrhythmias). Vascular studies were performed on 1.5-2 mm coronary segments (internal diameter 250-300 microns) removed distal to the site of occlusion and mounted in wire myographs for isometric tension recording. Area at risk and infarct size were determined by Indian ink injection and triphenyl tetrazolium staining, using computerized analysis of enlarged sections after colour video acquisition. 3. Bosentan, administered at a dose which virtually abolished the pressor response to big ET-1 (3 mg kg-1, i.v. before ischaemia) did not affect heart rate, arterial pressure or the rate pressure product before ischaemia, during ischaemia and during reperfusion. Bosentan did not affect the incidence of reperfusion-induced ventricular fibrillation (controls: 86%, n = 14; bosentan: 93%, n = 15), and did not modify infarct size (% of area at risk: controls: 63 +/- 4, n = 10; bosentan: 60 +/- 6, n = 8). Ischaemia followed by reperfusion markedly reduced the endothelium-dependent relaxations to acetylcholine(maximal response: sham: 59 +/- 4%, n = 9; ischaemia-reperfusion: 26+/- 6%, n = 8; P<0.01), characteristic of reperfusion-induced endothelial dysfunction, and this dysfunction was not prevented by bosentan (maximal response to acetylcholine: 25 +/-5%, n = 9; P<0.01 vs sham; P = NS vs ischaemia/reperfusion).4. These experiments suggest that endogenous endothelin does not contribute to myocyte or coronary endothelial injury in this rat model of ischaemia and reperfusion.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7858879      PMCID: PMC1510467          DOI: 10.1111/j.1476-5381.1994.tb17073.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  53 in total

Review 1.  Molecular characterization of endothelin receptors.

Authors:  T Sakurai; M Yanagisawa; T Masaki
Journal:  Trends Pharmacol Sci       Date:  1992-03       Impact factor: 14.819

Review 2.  Atherosclerosis or lipoprotein-induced endothelial dysfunction. Potential mechanisms underlying reduction in EDRF/nitric oxide activity.

Authors:  N A Flavahan
Journal:  Circulation       Date:  1992-05       Impact factor: 29.690

3.  Is big endothelin converted to endothelin-1 in circulating blood?

Authors:  Y Watanabe; M Naruse; C Monzen; K Naruse; K Ohsumi; J Horiuchi; I Yoshihara; Y Kato; N Nakamura; M Kato
Journal:  J Cardiovasc Pharmacol       Date:  1991       Impact factor: 3.105

4.  Subepicardial microischemia formation induced by epicardial application of endothelin-1.

Authors:  S Hori; S Kyotani; S Inoue; K Fukuda; Y Ohnishi; M Kusuhara; N Aikawa; K Yamaguchi; Y Nakamura; S Handa
Journal:  J Cardiovasc Pharmacol       Date:  1991       Impact factor: 3.105

5.  Heterogeneous involvement of endothelium in calcitonin gene-related peptide-induced relaxation in coronary arteries from rat.

Authors:  D Prieto; S Benedito; N C Nyborg
Journal:  Br J Pharmacol       Date:  1991-07       Impact factor: 8.739

6.  The effects of the endothelin ETA receptor antagonist, FR 139317, on infarct size in a rabbit model of acute myocardial ischaemia and reperfusion.

Authors:  L McMurdo; C Thiemermann; J R Vane
Journal:  Br J Pharmacol       Date:  1994-05       Impact factor: 8.739

7.  The transient nature of the effect of ischemic preconditioning on myocardial infarct size and ventricular arrhythmia.

Authors:  Y W Li; P Whittaker; R A Kloner
Journal:  Am Heart J       Date:  1992-02       Impact factor: 4.749

8.  Contribution of endogenous endothelin to the extension of myocardial infarct size in rats.

Authors:  T Watanabe; N Suzuki; N Shimamoto; M Fujino; A Imada
Journal:  Circ Res       Date:  1991-08       Impact factor: 17.367

9.  The effects of phosphoramidon on the regional haemodynamic responses to human proendothelin [1-38] in conscious rats.

Authors:  S M Gardiner; A M Compton; P A Kemp; T Bennett
Journal:  Br J Pharmacol       Date:  1991-08       Impact factor: 8.739

10.  Effects of endothelin-1 in the isolated heart in ischemia/reperfusion and hypoxia/reoxygenation injury.

Authors:  S Neubauer; S Zimmermann; A Hirsch; F Pulzer; R Tian; W Bauer; B Bauer; G Ertl
Journal:  J Mol Cell Cardiol       Date:  1991-12       Impact factor: 5.000

View more
  9 in total

Review 1.  Do endothelin receptor antagonists have an antiarrhythmic potential during acute myocardial infarction? Evidence from experimental studies.

Authors:  Dimitrios L Oikonomidis; Giannis G Baltogiannis; Theofilos M Kolettis
Journal:  J Interv Card Electrophysiol       Date:  2010-06-08       Impact factor: 1.900

Review 2.  Coronary vasoregulation in health and disease.

Authors:  John G Kingma; Jacques R Rouleau
Journal:  Can J Cardiol       Date:  2007-10       Impact factor: 5.223

3.  Combined blockade of endothelin-1 and thromboxane A(2) receptors against postischaemic contractile dysfunction in rat hearts.

Authors:  P S Hornstein; C E Zaugg; P Zhu; P R Allegrini; P T Buser
Journal:  Br J Pharmacol       Date:  2001-01       Impact factor: 8.739

4.  Bosentan, the mixed ETA-ETB endothelin receptor antagonist, attenuated oxidative stress after experimental myocardial ischemia and reperfusion.

Authors:  Suresh K Gupta; Amit Saxena; Uma Singh; Dharamvir S Arya
Journal:  Mol Cell Biochem       Date:  2005-07       Impact factor: 3.396

5.  What is the required reperfusion period for assessment of myocardial infarct size using triphenyltetrazolium chloride staining in the rat?

Authors:  E R Schwarz; Y Somoano; S L Hale; R A Kloner
Journal:  J Thromb Thrombolysis       Date:  2000-10       Impact factor: 2.300

6.  Characterization of the endothelin receptor selective agonist, BQ3020 and antagonists BQ123, FR139317, BQ788, 50235, Ro462005 and bosentan in the heart.

Authors:  M G Peter; A P Davenport
Journal:  Br J Pharmacol       Date:  1996-02       Impact factor: 8.739

7.  Myocardial and coronary endothelial protective effects of acetylcholine after myocardial ischaemia and reperfusion in rats: role of nitric oxide.

Authors:  V Richard; T Blanc; N Kaeffer; C Tron; C Thuillez
Journal:  Br J Pharmacol       Date:  1995-08       Impact factor: 8.739

8.  Involvement of Endothelin 1 in Remote Preconditioning-Induced Cardioprotection through connexin 43 and Akt/GSK-3β Signaling Pathway.

Authors:  Min Zhang; Wei Wei Gu; Xing Yu Hong
Journal:  Sci Rep       Date:  2018-07-19       Impact factor: 4.379

9.  Myocardial protective effect of tezosentan, an endothelin receptor antagonist, for ischemia-reperfusion injury in experimental heart failure models.

Authors:  Se Min Ryu; Hark Jei Kim; Kyu Ran Cho; Won-Min Jo
Journal:  J Korean Med Sci       Date:  2009-09-23       Impact factor: 2.153

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.